Importer of Controlled Substances Application: Fisher Clinical Services, Inc., 62118 [2022-22268]

Download as PDF 62118 Federal Register / Vol. 87, No. 197 / Thursday, October 13, 2022 / Notices DEPARTMENT OF JUSTICE Drug code Controlled substance Schedule Drug Enforcement Administration [Docket No. DEA–1095] Importer of Controlled Substances Application: Fisher Clinical Services, Inc. Drug Enforcement Administration, Justice. ACTION: Notice of application. AGENCY: Fisher Clinical Services, Inc has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to SUPPLEMENTARY INFORMATION listed below for further drug information. DATES: Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may submit electronic comments on or objections to the issuance of the proposed registration on or before November 14, 2022. Such persons may also file a written request for a hearing on the application on or before November 14, 2022. ADDRESSES: The Drug Enforcement Administration requires that all comments be submitted electronically through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment field on the web page or attach a file for lengthier comments. Please go to https://www.regulations.gov and follow the online instructions at that site for submitting comments. Upon submission of your comment, you will receive a Comment Tracking Number. Please be aware that submitted comments are not instantaneously available for public view on https://www.regulations.gov. If you have received a Comment Tracking Number, your comment has been successfully submitted and there is no need to resubmit the same comment. All requests for a hearing must be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a hearing should also be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this is notice that on September 20, 2022, Fisher Clinical Services, Inc, 700A–C Nestle Way, Breinigsville, Pennsylvania 18031–1522, applied to be registered as an importer of the following basic class(es) of controlled substance(s): khammond on DSKJM1Z7X2PROD with NOTICES SUMMARY: VerDate Sep<11>2014 17:49 Oct 12, 2022 Jkt 259001 Marihuana Extract ........ Psilocybin ..................... Methylphenidate ........... Levorphanol .................. Noroxymorphone .......... Tapentadol .................... 7350 7437 1724 9220 9668 9780 I I II II II II The company plans to import the listed controlled substance(s) for use in clinical trials only. No other activity for these drug codes are authorized for this registration. Approval of permit applications will occur only when the registrant’s business activity is consistent with what is authorized under 21 U.S.C. 952(a)(2). Authorization will not extend to the import of Food and Drug Administration-approved or nonapproved finished dosage forms for commercial sale. Kristi O’Malley, Assistant Administrator. [FR Doc. 2022–22268 Filed 10–12–22; 8:45 am] BILLING CODE P DEPARTMENT OF LABOR Agency Information Collection Activities; Claim for ReimbursementAssisted Reemployment Notice of availability; request for comments. ACTION: The Department of Labor (DOL) is submitting this Office of Workers’ Compensation Programs (OWCP)-sponsored information collection request (ICR) to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995 (PRA). Public comments on the ICR are invited. DATES: The OMB will consider all written comments that the agency receives on or before November 14, 2022. SUMMARY: Written comments and recommendations for the proposed information collection should be sent within 30 days of publication of this notice to www.reginfo.gov/public/do/ PRAMain. Find this particular information collection by selecting ‘‘Currently under 30-day Review—Open for Public Comments’’ or by using the search function. Comments are invited on: (1) whether the collection of information is necessary for the proper performance of the functions of the Department, including whether the information will ADDRESSES: PO 00000 Frm 00053 Fmt 4703 Sfmt 4703 have practical utility; (2) the accuracy of the agency’s estimates of the burden and cost of the collection of information, including the validity of the methodology and assumptions used; (3) ways to enhance the quality, utility and clarity of the information collection; and (4) ways to minimize the burden of the collection of information on those who are to respond, including the use of automated collection techniques or other forms of information technology. FOR FURTHER INFORMATION CONTACT: Nicole Bouchet by telephone at 202– 693–0213, or by email at DOL_PRA_ PUBLIC@dol.gov. To aid in the employment of Federal employees with disabilities related to an on-the-job injury, employers submit Form CA– 2231 to claim reimbursement for wages paid under the assisted reemployment project. This information allows for a prompt decision on payment. For additional substantive information about this ICR, see the related notice published in the Federal Register on August 2, 2022 (87 FR 47232). This information collection is subject to the PRA. A Federal agency generally cannot conduct or sponsor a collection of information, and the public is generally not required to respond to an information collection, unless the OMB approves it and displays a currently valid OMB Control Number. In addition, notwithstanding any other provisions of law, no person shall generally be subject to penalty for failing to comply with a collection of information that does not display a valid OMB Control Number. See 5 CFR 1320.5(a) and 1320.6. DOL seeks PRA authorization for this information collection for three (3) years. OMB authorization for an ICR cannot be for more than three (3) years without renewal. The DOL notes that information collection requirements submitted to the OMB for existing ICRs receive a month-to-month extension while they undergo review. Agency: DOL–OWCP. Title of Collection: Claim for Reimbursement-Assisted Reemployment. OMB Control Number: 1240–0018. Affected Public: Private Sector— Businesses or other for-profits. Total Estimated Number of Respondents: 14. Total Estimated Number of Responses: 56. Total Estimated Annual Time Burden: 28 hours. Total Estimated Annual Other Costs Burden: $0. SUPPLEMENTARY INFORMATION: E:\FR\FM\13OCN1.SGM 13OCN1

Agencies

[Federal Register Volume 87, Number 197 (Thursday, October 13, 2022)]
[Notices]
[Page 62118]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-22268]



[[Page 62118]]

-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-1095]


Importer of Controlled Substances Application: Fisher Clinical 
Services, Inc.

AGENCY: Drug Enforcement Administration, Justice.

ACTION: Notice of application.

-----------------------------------------------------------------------

SUMMARY: Fisher Clinical Services, Inc has applied to be registered as 
an importer of basic class(es) of controlled substance(s). Refer to 
Supplementary Information listed below for further drug information.

DATES: Registered bulk manufacturers of the affected basic class(es), 
and applicants therefore, may submit electronic comments on or 
objections to the issuance of the proposed registration on or before 
November 14, 2022. Such persons may also file a written request for a 
hearing on the application on or before November 14, 2022.

ADDRESSES: The Drug Enforcement Administration requires that all 
comments be submitted electronically through the Federal eRulemaking 
Portal, which provides the ability to type short comments directly into 
the comment field on the web page or attach a file for lengthier 
comments. Please go to https://www.regulations.gov and follow the 
online instructions at that site for submitting comments. Upon 
submission of your comment, you will receive a Comment Tracking Number. 
Please be aware that submitted comments are not instantaneously 
available for public view on https://www.regulations.gov. If you have 
received a Comment Tracking Number, your comment has been successfully 
submitted and there is no need to resubmit the same comment. All 
requests for a hearing must be sent to: (1) Drug Enforcement 
Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive, 
Springfield, Virginia 22152; and (2) Drug Enforcement Administration, 
Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, 
Springfield, Virginia 22152. All requests for a hearing should also be 
sent to: Drug Enforcement Administration, Attn: Administrator, 8701 
Morrissette Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this 
is notice that on September 20, 2022, Fisher Clinical Services, Inc, 
700A-C Nestle Way, Breinigsville, Pennsylvania 18031-1522, applied to 
be registered as an importer of the following basic class(es) of 
controlled substance(s):

------------------------------------------------------------------------
                                           Drug
          Controlled substance             code          Schedule
------------------------------------------------------------------------
Marihuana Extract......................     7350  I
Psilocybin.............................     7437  I
Methylphenidate........................     1724  II
Levorphanol............................     9220  II
Noroxymorphone.........................     9668  II
Tapentadol.............................     9780  II
------------------------------------------------------------------------

    The company plans to import the listed controlled substance(s) for 
use in clinical trials only. No other activity for these drug codes are 
authorized for this registration.
    Approval of permit applications will occur only when the 
registrant's business activity is consistent with what is authorized 
under 21 U.S.C. 952(a)(2). Authorization will not extend to the import 
of Food and Drug Administration-approved or non-approved finished 
dosage forms for commercial sale.

Kristi O'Malley,
Assistant Administrator.
[FR Doc. 2022-22268 Filed 10-12-22; 8:45 am]
BILLING CODE P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.